Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

RaySearch signs agreement with B dot Medical for development of advanced software solutions for proton therapy

RaySearch Laboratories AB (publ) is pleased to announce a strategic collaboration agreement with B dot Medical Inc. aimed at advancing the field of proton therapy by development and validation of intregrations between RaySearch’s treatment planning system RayStation®*, oncology information system RayCare®* and B dot Medical’s ultra-compact proton therapy system.B dot Medical is a Japanese company dedicated to the development of an ultra-compact proton therapy system with a non-rotating gantry, which is focused on achieveing exceptional irradiation performance, including cutting-edge

DNV AS to commence redemption proceedings in respect of the remaining minority shares in Nixu Corporation

Nixu Corporation, Stock Exchange Release, June 13, 2023, 3.00 p.m. EETNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THIS TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. On June 8, 2023, DNV AS (the “Offeror”) announced that it will complete the voluntary recommended public cash tender offer to acquire all the issued and outstanding shares in Nixu Corporation (“Nixu” or the “Company”) that are not held by Nixu or any of its

The Board of Directors of Nixu Corporation has decided on a directed share issue without consideration

Nixu Corporation, Stock Exchange Release, June 13, 2023, 3.00 p.m. EETThe Board of Directors of Nixu Corporation (the “Company”) has on today June 13, 2023 decided on a directed share issue of 44 000 shares (the “New Shares”) without consideration to the CEO Teemu Salmi under the Matching Share Plan 2022 (the “Matching Share Plan”). In accordance with the terms and conditions of the Matching Share Plan, the Company shall resolve to settle all share rewards under the Matching Share Plan and the Matching Share Plan shall terminate if a public tender offer has been made for all shares in

Sitowise Group Oyj - Managers' Transactions - Wäck

Sitowise Group Plc Stock Exchange Release 13 June 2023 at 2.30 p.m. (EEST) ____________________________________________ Person subject to the notification requirement Name: Anna Wäck Position: Other senior manager  Issuer: Sitowise Group Oyj LEI: 743700HOHMOHAANHFF73 Notification type: INITIAL NOTIFICATION Reference number: 33200/5/8 ____________________________________________ Transaction date: 2023-06-06 Outside a trading venue Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of the instrument: 2021A Nature of

Enersense delivers high-power charging stations to Vocational Education Centre in the Jokilaaksot region

Enersense International PlcPress release 13 June 2023 at 2:05 p.m.Enersense Charging Oy, a manufacturer of high-power charging stations for electric vehicles, has won the delivery of electric vehicle charging stations to Vocational Education Centre JEDU in a public procurement tendering. Two 160 kW high-power charging stations will be delivered to the Vocational Education Centre in the Jokilaaksot region, for example for charging electric trucks and vans, as well as for training projects. “Interest in our new high-power charging station has been great. Due to its high-performance,

Bioretec Ltd invests in a CNC machining center to increase the RemeOsTM production capacity

Bioretec Ltd   Press release   13 June 2023 at 02:00 p.m. EESTBioretec Ltd, a pioneer in bioresorbable orthopedic implants, has acquired a new CNC machining center to increase the production capacity of RemeOs™ products at its factory in Tampere, Finland. The acquired machine is optimized for the production of magnesium-based implants and especially for the first product from the RemeOsTM product family, the RemeOsTM screw, which was granted market authorization in the U.S. in March 2023.   "The new CNC machining center will significantly increase our production capacity of RemeOs™

Clinical Laserthermia Systems receives additional pre-subscription commitments and top-level underwriting commitments in the upcoming rights issue of units

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.   Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") hereby informs that the Company has

1,5 million blood bags discarded each year due to transport and storage issues

More than 1,5 million blood bags are discarded every year after transportation and storage problems, according to the World Health Organization, WHO.[1] Meanwhile, there is a blood shortage during operations, even though 118,5 million blood bags are altruistically donated by people all over the world,[2] for the sake of others.One unit of blood can save up to three lives and can only be aggregated through human donors. 1,5 million wasted blood bags equals 4,5 million potential saved lives each year. This also means that every year, blood worth up to € 350 million goes to waste - equivalent

PFAS-Free for the Future

Fogmaker International AB introduces a new fire suppression fluid on the Swedish market.Fogmaker International has spent years developing and evaluating fire suppression liquids free of PFAS chemicals to find the most effective solution. When combined with an optimized Fogmaker system, the new Eco 1 liquid is unique in being 100% free from PFAS chemicals while also managing all three sides of the fire triangle: heat, oxygen, and fuel. Fogmaker has carried out and passed fire suppression tests with Eco 1 according to SPCR 183 and the SBF 127:17 regulations. Starting January 1st, 2024, SBF

Positive profit warning: Finnair updates its profit outlook for 2023

Finnair Plc              Inside information               13 June 2023 at 12.00 p.m. EEST Finnair raises its guidance for comparable operating result for the full year 2023, as it expects the travel demand to continue stronger than previously anticipated, fuel price development has been more favourable than expected and as the company’s strategy implementation has progressed better than anticipated. Contrary to the previous guidance, the company estimates that the comparable operating result will probably reach or even exceed the 2019 level (162.8 million euros). In terms of 2023

WindowMaster International A/S signs one more partner in Holland

Investor News No. 007 - 2023WindowMaster has established yet another partnership with a Dutch company specializing in building automation and skylights. Based in Ede, the new partner company will be able to push, plan, and execute projects with WindowMasters’ solutions. The partnership will focus on promoting natural ventilation solutions, including hardware (actuators and controls) and our expertise in the field. According to expert sources, Holland is leading the introduction of circularity to the international construction sector due to the country’s high sustainable objectives and

Pharmacolog presents new strategy at Småbolagsdagarna 2023

Lars Gusch, CEO of Pharmacolog i Uppsala AB (publ) presented the company’s new strategic direction at Småbolagsdagarna, June 12th, 2023.Pharmacolog paves the way for strong commercial development. By broadening the distribution network and introducing a SaaS model to lower the initial investment, more hospitals can implement quality control of compounded pharmaceuticals and thereby increase patient safety.  The live streamed event was arranged by Aktiespararna and the presentation (in Swedish) has been made available on the company website https://pharmacolog.com/investor-relations-2/.

Peptonic's patent application is approved in the US as first country

Peptonic Medical AB (publ) today announced that the application to patent its intimate cleanser in US will be approved on June 20th 2023, this according to information from the USPTO (United States Patent and Trademark Office).“This is an important step to increase the attractiveness of our portfolio in the eyes of consumers and distribution partners in the US”, says Erik Sundquist, CEO of Peptonic Medical The global intimate cleanser market is ca 1.2 billion USD growing at an annual rate of ca 3,5%. Somewhat simplified the market constitutes of soaps and oils. With soaps there is a risk

IFS and HOIST launch FLEXPLUS Enterprise Applications Services

The strategic partners have jointly developed FLEXPLUS as an alternative to IFS’s Services that is well suited to mid-size customers as they embark on their IFS journeyLondon, UK, June 13, 2023 - IFS, the global enterprise applications company, has today announced that it has partnered with HOIST, already a strategic partner in the IFS Ecosystem, to develop and deliver a mid-market specialised service offering to help further drive customer satisfaction in the IFS ecosystem.  Mid-size companies are also under pressure to modernize their systems and build new capabilities to keep

Assemblin announces the offering of €480 million senior secured floating rate notes due 2029

NOT FOR DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATIONOF U.S. SECURITIES LAW. In order to read the press release, please download it via the news flow  at our web page. For more information, contact:Åsvor Brynnel, Head of Communications and Sustainability, asvor.brynnel@assemblin.se, +46 70 600 73 21Philip Carlsson, CFO, philip.carlsson@assemblin.se, +46 10 475

Storytel enters strategic partnership with ElevenLabs and announces upcoming launch of new VoiceSwitcher feature

Storytel, one of the world’s largest subscription services for audiobook streaming, today announced an exclusive partnership with the leading AI speech software provider ElevenLabs. The collaboration will involve the development of AI voices specifically tailored to Storytel’s core markets and the production of AI narrated audiobooks. A new VoiceSwitcher feature will allow enhanced personalization of the Storytel service at scale, facilitating truly unique listening experiences customized for every ear.Founded in 2022, US-based ElevenLabs has rapidly grown to become one of the world’s

Michael Björklund appointed Business Unit President for Bonava Sweden

Michael Björklund has been appointed as the new Business Unit President for Bonava Sweden. He will take office on 1 September and will also continue to be responsible for Bonava’s operations in the Baltics.–  Michael Björklund has broad experience and in-depth expertise of residential development, which makes him the right person to lead Bonava Sweden going forward. By focusing on its commercial activities, Bonava in the Baltics has developed into the Group’s most profitable business unit under his leadership, says Peter Wallin, President and CEO of Bonava. Michael Björklund is currently

SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow

SyntheticMR has released a new update to SyMRI 11.3.11 & 12.1.11 that provides condensed and relevant quantitative neuro report for both radiologists and providers.SyntheticMR's Quantitative Neuro Report is a user-friendly solution.  These reports provide:  •    Automated quantification of brain volumetrics •    Normative age-stratified reference curves •    Myelin volume and distribution •    A compatible format with most RIS/EMR systems, including DICOM SR and PDF encapsulated DICOM.  Dr. David Lefkowitz of SimonMed has collaborated with Synthetic MRI in the understanding

Reltime unveils Non-Custodian Mobile Wallets and Revolutionary Web3 Platform to democratize Global Digital Finance

OSLO, Norway - Reltime AS, a leading innovator of digital financial solutions has announced today that it is launching the next version of its non-custodian wallets and ground-breaking Web3 platform which are set to revolutionize global digital finance. In May 2023, Reltime won the prestigious Nordic Innovation Award as the Best AI & Web3 Fintech of 2023 (news link here ). "Reltime is dedicated to empowering customers worldwide by

Mandatory notification of trade by Primary Insiders and close associates

Bergen 13 June 2023: Reference is made to the stock exchange announcement published by BerGenBio ASA (the "Company") on 30 May 2023, regarding the commencement of the subscription period in the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of the Company. The Company has been informed that Sarsia Development AS, a company closely associated to Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, on 12 June 2023, exercised 33,131,992 subscription rights

BioStock: Chosa develops next generation chemotherapy

The chemotherapy cisplatin has been a staple in cancer treatment since the 1980s. However, not all cancer patients respond to the drug, and the side effects are quite severe. Chosa Oncology is looking to tackle both of these drawbacks with its iCIP concept. BioStock has taken a closer look at this revolutionary cancer treatment and how the company is working to take it to the next level.Read the full article at biostock.se : https://www.biostock.se/en/2023/06/chosa-develops-next-generation-chemotherapy/ This is a press release from BioStock - Connecting

There are no items matching the current filter
There are no more items matching the current filter
Back to top